Standard BioTools Inc. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Standard BioTools Inc. payments for repurchase of common stock for the quarter ending 2025-12-31 was $0.00.
- Standard BioTools Inc. payments for repurchase of common stock for the quarter ending 2025-09-30 was $0.00.
- Standard BioTools Inc. payments for repurchase of common stock for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Standard BioTools Inc. payments for repurchase of common stock for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Standard BioTools Inc. payments for repurchase of common stock for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Standard BioTools Inc. payments for repurchase of common stock for fiscal 2024 was $40.49M, a 647.88% increase from fiscal 2023.
- Standard BioTools Inc. payments for repurchase of common stock for fiscal 2023 was $5.41M, a 861.63% increase from fiscal 2022.
- Standard BioTools Inc. payments for repurchase of common stock for fiscal 2022 was $563.00K.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 10-K · filed 2026-03-16 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | $0.00 derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 | $29.44M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $40.49M 10-K · filed 2026-03-16 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $40.66M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-06-30 | $29.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | $41.06M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-03-31 | $11.05M 10-Q · filed 2025-05-06 | $14.03M derived: sum of 4 quarters · filed 2026-03-16 |
| 2023-12-31 | $174.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $5.41M 10-K · filed 2026-03-16 |
| 2023-09-30 | $400.00K 10-Q · filed 2023-11-07 | $5.83M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $2.40M 10-Q · filed 2023-08-08 | $5.43M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $2.47M 10-Q · filed 2024-05-09 | $3.03M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $563.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $563.00K 10-K · filed 2025-03-11 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |